Key Takeaway: CG Oncology has announced positive preliminary results from its CORE-1008 Phase 2 trial, which evaluates an intravesical combination therapy for patients who are high-risk and either BCG-exposed or BCG-unresponsive. Additionally, the company will present at upcoming investor conferences and has recognized recipients for the NMIBC research fellowship.
Price reaction · baseline $28.53 (2025-03-24 close) · hit pre-market · 1 other CGON headline(s) in the window, move may be shared
day 0 close · peak
-3.5%
Market Sentiment Analysis
POSITIVE FACTORS
CG Oncology reports positive results from CORE-1008 trial.
The company is actively engaging in investor conferences.
Award recipients announced for NMIBC research fellowship.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer
Full Press Release Details
by admin | Mar 25, 2025 | in-the-news
Recent Posts
• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation
Recent Comments
Frequently Asked Questions
What are the results of the CORE-1008 trial?
CG Oncology reported positive preliminary results from the CORE-1008 Phase 2 trial.
What is the focus of the CORE-1008 trial?
The trial evaluates an intravesical combination therapy for high-risk BCG-exposed and BCG-unresponsive patients.
When will CG Oncology present at investor conferences?
CG Oncology is scheduled to present at upcoming investor conferences in June.
What fellowship award was announced by CG Oncology?
CG Oncology announced the award recipients for the second annual NMIBC research fellowship.